ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA

ARK Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 8.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,919,178 shares of the company’s stock after selling 1,098,698 shares during the quarter. Intellia Therapeutics makes up about 1.2% of ARK Investment Management LLC’s investment portfolio, making the stock its 23rd largest holding. ARK Investment Management LLC owned about 10.29% of Intellia Therapeutics worth $205,844,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NTLA. Headlands Technologies LLC bought a new position in Intellia Therapeutics in the second quarter worth $26,000. Blue Bell Private Wealth Management LLC purchased a new position in Intellia Therapeutics during the 3rd quarter valued at about $30,000. Newbridge Financial Services Group Inc. purchased a new position in Intellia Therapeutics during the 2nd quarter valued at about $52,000. Federated Hermes Inc. boosted its stake in Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after acquiring an additional 927 shares in the last quarter. Finally, Johnson Financial Group Inc. grew its holdings in Intellia Therapeutics by 24.8% in the second quarter. Johnson Financial Group Inc. now owns 6,988 shares of the company’s stock worth $66,000 after purchasing an additional 1,388 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Up 1.6%

Shares of NTLA opened at $13.82 on Thursday. The firm has a fifty day simple moving average of $12.17 and a two-hundred day simple moving average of $13.10. The firm has a market cap of $1.63 billion, a PE ratio of -3.61 and a beta of 2.10. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same period last year, the business posted ($1.27) EPS. The company’s revenue for the quarter was up 78.4% on a year-over-year basis. As a group, research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. HC Wainwright boosted their price target on Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Citizens Jmp boosted their target price on Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a report on Tuesday. Leerink Partners raised their price target on Intellia Therapeutics from $27.00 to $29.00 and gave the company an “outperform” rating in a report on Tuesday. Wells Fargo & Company lifted their price target on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, William Blair raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday. Eleven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.59.

Insiders Place Their Bets

In related news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP James Basta sold 10,397 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president owned 101,528 shares of the company’s stock, valued at $935,072.88. This trade represents a 9.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,051 shares of company stock valued at $488,600. Insiders own 3.10% of the company’s stock.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.